Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan Liposomes + Nituzumab in Recurrent/Metastatic Nasopharyngeal Carcinoma
NCT06414577Phase 2Active, not recruiting
- Start
- May 2024
- Primary completion
- Mar 2025
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 2 trial of nanoliposomal irinotecan, nimotuzumab in nasopharyngeal carcinoma (NPC). Started May 2024; status: active, not recruiting.
02
Drugs
nanoliposomal irinotecannimotuzumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT06414577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06414577.